Serina Therapeutics (SER)
:SER
Want to see SER full AI Analyst Report?
Total Valuation
Serina Therapeutics has a market cap or net worth of $25.00M. The enterprise value is $20.59M.
Market Cap$25.00M
Enterprise Value$20.59M
Share Statistics
Serina Therapeutics has 12,314,159 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,314,159
Owned by Insiders1.51%
Owned by Institutions0.34%
Financial Efficiency
Serina Therapeutics’s return on equity (ROE) is 518.43 and return on invested capital (ROIC) is -709.03%.
Return on Equity (ROE)518.43
Return on Assets (ROA)-2.76
Return on Invested Capital (ROIC)-709.03%
Return on Capital Employed (ROCE)-7.09
Revenue Per Employee10.83K
Profits Per Employee-1.62M
Employee Count12
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Serina Therapeutics is ―. Serina Therapeutics’s PEG ratio is -0.04.
PE Ratio―
PS Ratio149.71
PB Ratio-526.02
Price to Fair Value-526.02
Price to FCF-1.08
Price to Operating Cash Flow-1.16
PEG Ratio-0.04
Income Statement
In the last 12 months, Serina Therapeutics had revenue of 130.00K and earned -19.18M in profits. Earnings per share was -1.91.
Revenue130.00K
Gross Profit45.00K
Operating Income-24.02M
Pretax Income-19.20M
Net Income-19.18M
EBITDA-24.02M
Earnings Per Share (EPS)-1.91
Cash Flow
In the last 12 months, operating cash flow was -17.95M and capital expenditures -13.00K, giving a free cash flow of -17.97M billion.
Operating Cash Flow-17.95M
Free Cash Flow-17.97M
Free Cash Flow per Share-1.46
Dividends & Yields
Serina Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.19
52-Week Price Change-61.10%
50-Day Moving Average1.93
200-Day Moving Average3.76
Relative Strength Index (RSI)50.11
Average Volume (3m)24.47K
Important Dates
Serina Therapeutics upcoming earnings date is May 19, 2026, After Close (Confirmed).
Last Earnings DateMar 25, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Serina Therapeutics as a current ratio of 1.71, with Debt / Equity ratio of -8491.89%
Current Ratio1.71
Quick Ratio1.71
Debt to Market Cap0.01
Net Debt to EBITDA0.12
Interest Coverage Ratio-112.78
Taxes
In the past 12 months, Serina Therapeutics has paid 18.00K in taxes.
Income Tax18.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Serina Therapeutics EV to EBITDA ratio is -0.69, with an EV/FCF ratio of -0.92.
EV to Sales127.71
EV to EBITDA-0.69
EV to Free Cash Flow-0.92
EV to Operating Cash Flow-0.92
Balance Sheet
Serina Therapeutics has $3.06M in cash and marketable securities with $3.14M in debt, giving a net cash position of -$86.00K billion.
Cash & Marketable Securities$3.06M
Total Debt$3.14M
Net Cash-$86.00K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 43.85%, with operating margin of -18478.46%, and net profit margin of -14755.38%.
Gross Margin43.85%
Operating Margin-18478.46%
Pretax Margin-14766.92%
Net Profit Margin-14755.38%
EBITDA Margin-18478.46%
EBIT Margin-18478.46%
Analyst Forecast
The average price target for Serina Therapeutics is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside436.59% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―